This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Antigenics CEO Discusses Q3 2010 Results - Earnings Call Transcript

Antigenics Inc, ( AGEN)

Q3 2010 Earnings Conference Call

October 28, 2010 11:00 am EST


Shalini Sharp - Antigenics - CFO

Garo Armen - Antigenics - Chairman, CEO


Jeff Lighter - Private Investor

Eric Warrick - Private Investor

Ren Benjamin - Rodman & Renshaw



Good morning, my name is Shawn, and I’ll be your conference operator today. At this time I would like to welcome everyone to the Antigenics Third Quarter 2010 Earnings Conference Call. (Operator instructions)

Thank you. Ms. Sharp, you may begin your conference.

Shalini Sharp

Thank you, Shawn and good morning everyone. Welcome to Antigenics conference call to discuss the financial results for the quarter ended September 30 th, 2010. With me today is Dr. Garo Armen, Chairman and CEO. We hope that all of you had a chance to review the press release that was issued this morning. During this call we will review the financial results as well as provide a corporate update. We will then have a Q&A session.

Before we continue, I would like to remind you that this conference call will contain forward-looking statements including, without limitation, statements development and commercialization efforts and timelines of the company, and/or its licensees, partnering efforts, and their potential impact on the company’s programs, timing of potential royalty streams and the potential efficacy of our product candidates.

These forward looking statements are subject to risks and uncertainty that could cause actual results to differ materially. Reference to these risks and uncertainties is made in today’s press release and they are disclosed in more detail in our most recent filings with the U.S. SEC. These statements speak only as of the date of this call, and Antigenics undertakes no obligation to update or revise the statements.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs